These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

654 related items for PubMed ID: 18957959

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. New anti-platelet agents: the end of resistance?
    Kastrati A.
    Thromb Res; 2012 Oct; 130 Suppl 1():S53-5. PubMed ID: 23026663
    [Abstract] [Full Text] [Related]

  • 24. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation.
    Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW.
    Thromb Haemost; 2009 Feb; 101(2):333-9. PubMed ID: 19190818
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Prasugrel: a novel platelet ADP P2Y receptor antagonist.
    Wilson W, Gurvitch R, Ajani AE.
    Cardiovasc Ther; 2009 Feb; 27(3):194-8. PubMed ID: 19689619
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. P2Y12 inhibitors: thienopyridines and direct oral inhibitors.
    Collet JP, Montalescot G.
    Hamostaseologie; 2009 Nov; 29(4):339-48. PubMed ID: 19882081
    [Abstract] [Full Text] [Related]

  • 31. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
    James S, Akerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, Skene A, Steg PG, Storey RF, Harrington R, Becker R, Wallentin L.
    Am Heart J; 2009 Apr; 157(4):599-605. PubMed ID: 19332184
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Update on antiplatelet therapy in acute coronary syndromes: what do new drugs bring into clinical practice?
    Heras M, del Río A.
    Am J Cardiovasc Drugs; 2009 Apr; 9 Suppl 1():13-7. PubMed ID: 20000883
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. P2Y12 inhibitors in cardiovascular disease: focus on prasugrel.
    Scott DM, Norwood RM, Parra D.
    Ann Pharmacother; 2009 Jan; 43(1):64-76. PubMed ID: 19050170
    [Abstract] [Full Text] [Related]

  • 39. Clinical overview of promising nonthienopyridine antiplatelet agents.
    Angiolillo DJ, Guzman LA.
    Am Heart J; 2008 Aug; 156(2 Suppl):S23-8. PubMed ID: 18657683
    [Abstract] [Full Text] [Related]

  • 40. Ticagrelor (Brilinta)--better than clopidogrel (Plavix)?
    Med Lett Drugs Ther; 2011 Sep 05; 53(1372):69-70. PubMed ID: 21897348
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 33.